98%
921
2 minutes
20
Background: Colorectal cancer (CRC) is a major cause of cancer mortality in the world. One of the most widely used screening tests for CRC is the immunochemical fecal occult blood test (iFOBT), which detects human hemoglobin from patient's stool sample. Although it is highly efficient in detecting blood from patients with gastro-intestinal lesions, such as polyps and cancers, the iFOBT has a high rate of false positive discovery. Recent studies suggested gut bacteria as a promising noninvasive biomarker for improving the diagnosis of CRC. In this study, we examined the composition of gut bacteria using iFOBT leftover from patients undergoing screening test along with a colonoscopy.
Methods: After collecting data from more than 800 patients, we considered 4 groups for this study. The first and second groups were respectively "healthy" in which the patients had either no blood in their stool or had blood but no lesions. The third and fourth groups of patients had both blood in their stools with precancerous and cancerous lesions and considered either as low-grade and high-grade lesion groups, respectively. An amplification of 16S rRNA (V4 region) gene was performed, followed by sequencing along with various statistical and bioinformatic analysis.
Results: We analyzed the composition of the gut bacteriome at phylum, class, genus, and species levels. Although members of the Firmicute phylum increased in the 3 groups compared to healthy patients, the phylum Actinobacteriota was found to decrease. Moreover, Blautia obeum and Anaerostipes hadrus from the phylum Firmicutes were increased and Collinsella aerofaciens from phylum Actinobacteriota was found decreased when healthy group is compared to the patients with high-grade lesions. Finally, among the 5 machine learning algorithms used to perform our analysis, both elastic net (AUC > 0.7) and random forest (AUC > 0.8) performs well in differentiating healthy patients from 3 other patient groups having blood in their stool.
Conclusion: Our study integrates the iFOBT screening tool with gut bacterial composition to improve the prediction of CRC lesions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clcc.2023.10.004 | DOI Listing |
BMJ Open Gastroenterol
September 2025
Manchester University NHS Foundation Trust, Manchester, UK.
Objective: People with cystic fibrosis (pwCF) are at significantly increased risk of colorectal cancer (CRC), prompting international recommendations for earlier screening with colonoscopy. The utility of faecal immunochemical testing (FIT) as a screening adjunct in pwCF remains unclear. This study evaluates FIT's diagnostic performance and uptake within a CRC screening programme in a UK CF centre.
View Article and Find Full Text PDFProbiotics Antimicrob Proteins
September 2025
Key Laboratory of the Ministry of Education for Wildlife and Plant Resources Conservation in Southwest China, College of Life Sciences, China West Normal University, Nanchong, Sichuan, China.
Enterotoxigenic Escherichia coli (ETEC) is a prevalent intestinal pathogen that significantly impacts both human and animal health. G83, isolated from giant panda feces, has demonstrated notable probiotic properties. In this study, C57BL/6 J mice were randomly divided into Control, ETEC, and G83 groups.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Importance: In colorectal cancer (CRC) screening, too many patients fail to receive follow-up colonoscopy after an abnormal fecal immunochemical test (FIT), and transportation is a frequently reported barrier.
Objective: To determine the outcomes and cost-effectiveness of providing a rideshare intervention to patients with abnormal FIT results.
Design, Setting, And Participants: The CRC-Simulated Population Model for Incidence and Natural History microsimulation model was used to simulate the outcomes and cost-effectiveness of a rideshare intervention to improve colonoscopy completion in a population-based CRC screening program.
Can J Gastroenterol Hepatol
September 2025
Department of Gastroenterology, St Luke's General Hospital, Kilkenny, Ireland.
The faecal immunochemical test (FIT) is endorsed by NICE for triaging symptomatic patients referred from primary care. This prospective diagnostic accuracy study assessed the performance of FIT in detecting significant colorectal pathology among symptomatic patients referred for colonoscopy in secondary care. Between May 2023 and May 2024, FIT kits were distributed to 1296 adult patients referred for lower gastrointestinal (GI) endoscopy.
View Article and Find Full Text PDFPLoS Med
September 2025
Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Although the fecal immunochemical test (FIT) is widely utilized in colorectal cancer (CRC) screening because of its noninvasive, rapid, and cost-effective characteristics, its effectiveness in post-adenoma resection surveillance remains unclear. This study aims to evaluate the benefits of follow-up FIT surveillance in individuals with adenoma resection and to identify risk factors associated with adenoma recurrence.
Methods And Findings: As part of China's National Screening Project, we identified a total of 5,911 individuals who underwent adenoma removal during the first round of CRC screening in Jiashan and Haining between 2006 and 2021.